Dopamine-induced cyclic AMP increase in canine myocardium, kidney and superior mesenteric artery.
The effect of dopamine on cyclic AMP levels in tissue slices of canine myocardium and kidney, and in chopped superior mesenteric arterial wall was investigated to identify dopamine receptors. Tissues were incubated in modified Krebs-Henseleit Ringer bicarbonate solution at 37 degrees C for 20 min with test drugs, after 20-min preincubation. In the presence of 3-isobutyl-1-methylxanthine (IBMX), dopamine and apomorphine caused dose-dependent increases in cyclic AMP levels in the myocardium, kidney and superior mesenteric artery. Phentolamine significantly intensified the cyclic AMP-increasing effect of dopamine in the superior mesenteric artery, but it did not influence the cyclic AMP increase caused by dopamine or apomorphine in the myocardium and kidney. Propranolol markedly blocked the effect of dopamine on cyclic AMP levels in all tissues studied. Haloperidol slightly inhibited the effect of dopamine and completely blocked the effect of apomorphine in the myocardium and kidney. These data suggest that dopamine increases cyclic AMP levels by activating predominantly beta-adrenergic receptors and partly dopamine receptors in the canine myocardium, kidney and superior mesenteric artery. The present results also suggest that dopamine acts not only on beta-adrenergic and dopamine receptors but also on alpha-adrenergic receptors in the superior mesenteric artery. Contrary to the activation of beta-adrenergic and dopamine receptors, the activation of alpha-adrenergic receptors resulted in a decrease in cyclic AMP levels in this tissue.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D000242:Cyclic AMP / Q000032:analysis*; D004285:Dogs; D004298:Dopamine / Q000494:pharmacology*; D006220:Haloperidol / Q000494:pharmacology; D066298:In Vitro Techniques; D007668:Kidney / Q000032:analysis*; D008638:Mesenteric Arteries / Q000032:analysis*; D009206:Myocardium / Q000032:analysis*; D010646:Phentolamine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D011954:Receptors, Dopamine / Q000032:analysis / Q000187:drug effects
D011954:Receptors, Dopamine; D011433:Propranolol; D000242:Cyclic AMP; D006220:Haloperidol; D001058:Apomorphine; D015056:1-Methyl-3-isobutylxanthine; D004298:Dopamine; D010646:Phentolamine